Research Paper Volume 13, Issue 21 pp 24449—24463

Small interfering RNA-induced silencing lncRNA PVT1 inhibits atherosclerosis via inactivating the MAPK/NF-κB pathway

Silencing PVT1 suppresses AS progression via downregulating the MAPK/NF-κB signaling pathway. (A) Cell viability measured by MTT assay; (B) Relative cell clones measured by colony experiment; (C) Relative EdU positive rates detected by EdU assay; (D) Relative apoptosis ratio detected by flow cytometry; (E) Relative cell cycle distribution; (F) Relative protein levels of cleaved caspase-3, PARP and cleaved caspase-9 detected by Western blot. Compared to the PVTI-DMSO group, * p p

Figure 7. Silencing PVT1 suppresses AS progression via downregulating the MAPK/NF-κB signaling pathway. (A) Cell viability measured by MTT assay; (B) Relative cell clones measured by colony experiment; (C) Relative EdU positive rates detected by EdU assay; (D) Relative apoptosis ratio detected by flow cytometry; (E) Relative cell cycle distribution; (F) Relative protein levels of cleaved caspase-3, PARP and cleaved caspase-9 detected by Western blot. Compared to the PVTI-DMSO group, * p < 0.05, ** p < 0.01. PVT1, plasmacytoma variant translocation 1; AS, atherosclerosis; MAPK, mitogen-activated protein kinase; NF-κB, Nuclear factor-kappa B; OD, optical value; EdU, 5-ethynyl-2’-deoxyuridine; PARP, PARP, poly(ADP-ribose) polymerase; DMSO, dimethyl sulfoxide.